Saha Saswati, Brannath Werner, Bornkamp Björn
Competence Centre for Clinical Trials, University of Bremen, Germany.
Novartis Pharma, Basel, Switzerland.
Stat Methods Med Res. 2020 Jul;29(7):1799-1817. doi: 10.1177/0962280219871969. Epub 2019 Sep 24.
Drug combination trials are often motivated by the fact that individual drugs target the same disease but via different routes. A combination of such drugs may then have an overall better effect than the individual treatments which has to be verified by clinical trials. Several statistical methods have been explored that discuss the problem of comparing a fixed-dose combination therapy to each of its components. But an extension of these approaches to multiple dose combinations can be difficult and is not yet fully investigated. In this paper, we propose two approaches by which one can provide confirmatory assurance with familywise error rate control, that the combination of two drugs at differing doses is more effective than either component doses alone. These approaches involve multiple comparisons in multilevel factorial designs where the type 1 error can be controlled first, by bootstrapping tests, and second, by considering the least favorable null configurations for a family of union intersection tests. The main advantage of the new approaches is that their implementation is simple. The implementation of these new approaches is illustrated with a real data example from a blood pressure reduction trial. Extensive simulations are also conducted to evaluate the new approaches and benchmark them with existing ones. We also present an illustration of the relationship between the different approaches. We observed that the bootstrap provided some power advantages over the other approaches with the disadvantage that there may be some error rate inflation for small sample sizes.
药物联合试验的动机通常是,单一药物虽针对同一种疾病,但作用途径不同。那么,这类药物的联合使用可能比单一治疗具有更好的总体效果,这一点必须通过临床试验来验证。已经探索了几种统计方法来讨论将固定剂量联合疗法与其各成分进行比较的问题。但是,将这些方法扩展到多剂量联合可能很困难,并且尚未得到充分研究。在本文中,我们提出了两种方法,通过这两种方法可以在控制家族性错误率的情况下提供确证保证,即两种不同剂量的药物联合使用比单独使用任何一种成分剂量更有效。这些方法涉及多级析因设计中的多重比较,其中第一类错误可以首先通过自抽样检验来控制,其次通过考虑联合交集检验族的最不利零假设配置来控制。新方法的主要优点是其实施简单。通过一个降压试验的真实数据示例说明了这些新方法的实施过程。还进行了广泛的模拟,以评估新方法并与现有方法进行比较。我们还展示了不同方法之间的关系。我们观察到,自抽样检验相对于其他方法具有一些功效优势,缺点是对于小样本量可能会出现一些错误率膨胀。